A comparative study of Sitagliptin- Glimepiride combinational therapy and Glimepiride monotherapy on the patients with diabetes mellitus after pancreatic biliary diseases including malignant disorders related subtotal pancreatectomy
Phase 2
- Conditions
- Diabetes mellitus after pancreatic biliary diseases including malignant disorders related subtotal pancreatectomy
- Registration Number
- JPRN-UMIN000004645
- Lead Sponsor
- Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(a) Patients with a history of total pancreatectomy. (b) Patients with insulin-dependent diabetes mellitus. (c) Patients with a history of severe cardiovascular or cerebrovascular disease or renal failure. (c) Patients have contraindication of Sitagliptin, Glimepiride and glucagon. (d) Patients with severe liver damage. (e) Patients are pregnant or patients breast-feeding, potentially pregnant. (f) Patients who are diagnosed to be ineligible by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Delta C-peptide in glucagon injection. (delta C-peptide = max C-peptide – base C-peptide) Comparison the mean of delta C-peptide from before treatment to the end of the study between Sitagliptin- Glimepiride combinational therapy and Glimepiride monotherapy
- Secondary Outcome Measures
Name Time Method